| This week's sponsor is Premier Research. | | | Heartbreak No Longer: Winning the Battle Against Psoriasis
New treatments have broken the cycle of despair for people with severe psoriasis. Learn about the latest advances — and what to expect next — at our March 29 webinar. Register today. Premier Research. It's what we do. Best. |
Featured Story Thursday, March 9, 2017 With pricing pressure mounting in the diabetes space, insulin specialist Novo Nordisk may be looking to wean itself off its core focus with a rumored buyout for Global Blood Therapeutics, a buy that could help boost its own blood disorder business. Top Stories Thursday, March 9, 2017 Bristol-Myers Squibb has appointed Thomas Lynch to replace Francis Cuss as CSO. The reshuffle puts the former CEO of Massachusetts General Physicians Organization in charge of returning the lustre to Bristol-Myers’ R&D pipeline after a period in which setbacks to Opdivo have dampened expectations. Thursday, March 9, 2017 Cancer therapeutics biotech BeyondSpring scored $54.3 million in a combination IPO and private placement. The total falls well short of its initial $100 million target and relied almost exclusively on the placement for the bulk of its cut-price raise. Thursday, March 9, 2017 Nonprofit Parkinson’s UK has teamed up with the University of Sheffield to create a virtual biotech. The single-asset startup will work with service providers to advance an Nrf2 inhibitor toward the clinic. Thursday, March 9, 2017 Buoyed by a third-round fundraising that netted $51.7 million, antibiotic developer Spero Therapeutics says it will be able to accelerate clinical development of two drugs against drug-resistant infections recently highlighted by the WHO. Wednesday, March 8, 2017 Patient recruitment has been named as a key factor for clinical trial failures and delays, and many CROs are turning their studies to vast populated Asian countries, boosting the region’s trial industry, a recent Frost & Sullivan report finds. Thursday, March 9, 2017 The rumors are true: When it comes to biosimilars, Merck KGaA has had enough. The German drugmaker is in advanced negotiations to sell its unit of biologic copycats, it said in its 2016 annual report. | | | The FDA cleared Servier and Pfizer for U.S. trials of their CALM study for UCART19 in blood cancer, following the U.K. trial that started last year. Release On the day BMS lost its CSO, Epizyme has also said its head of research and chief scientific officer, Robert Copeland, has retired from the biotech. Statement The FDA has handed out its orphan drug designation tag for Boehringer's experimental anti-CD33 mAb in myelodysplastic syndromes. Release | |
|
Resources Presented By: Veeva Share your thoughts on the life sciences industry’s progress in reducing system and process complexity to improve study execution. The first 50 qualified respondents will receive a $10 Amazon gift card, as well as a $10 donation made to Doctors Without Borders in their name. Finish the survey today! Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA MIXiii-BIOMED 2017 May 23-25, 2017 | Tel Aviv, Israel | 